Titilope Omisakin, APRN
Psychiatric/Mental Health · Plymouth, MNNPI 1407536345
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 29 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 15.9% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in MN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 29 payments — averaging $17.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$82
- Tris Pharma Inc$68
- Ironshore Pharmaceuticals Inc.$62
- Neuronetics, Inc.$54
- Sage Therapeutics, LLC$52
- Vanda Pharmaceuticals Inc.$35
- plus $162 from 10 others
What the payments were for
- Food & beverage$515100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$515 in reported general payments places this provider in the 90th percentile of 407 psychiatric/mental health providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Quetiapine Fumarate | 25 | $1,811 |
| Lamotrigine | 37 | $867 |
| Escitalopram Oxalate | 43 | $607 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 11 | $530 |
| Aripiprazole | 16 | $501 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 19 | $444 |
| Mirtazapine | 23 | $360 |
| Buspirone Hcl | 23 | $325 |
| Trazodone Hcl | 32 | $269 |
| Duloxetine Hcl | 17 | $261 |
| Bupropion Hcl | 22 | $239 |
| Fluoxetine Hcl | 33 | $228 |
| Hydroxyzine Hcl | 12 | $226 |
| Oxcarbazepine | 12 | $164 |
| Bupropion XlBupropion Hcl | 18 | $152 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Plymouth
- John NwabugwuPlymouth$374
- Jacqualine GervaisMoorhead$29K
- Naomi KoenigSandstone$8K
- Dana BageonWayzata$7K
- Jill ScottAnoka$5K
- Holly WillisMinneapolis$5K
- Gerard BalanMinneapolis$5K
- Hilary BreedonShakopee$3K
- Tina AlexanderEdina$3K
- Twilla OskeyBaxter$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.